|1.||Ball, P: 5 articles (05/2004 - 07/2000)|
|2.||Tillotson, Glenn: 4 articles (04/2008 - 02/2004)|
|3.||Aguilar, L: 4 articles (02/2005 - 02/2000)|
|4.||Woodnutt, G: 4 articles (07/2000 - 03/2000)|
|5.||Blondeau, Joseph M: 3 articles (12/2009 - 05/2004)|
|6.||Tillotson, Glenn S: 3 articles (12/2009 - 12/2004)|
|7.||Zhanel, George G: 3 articles (12/2007 - 01/2002)|
|8.||Hoban, Daryl J: 3 articles (12/2007 - 01/2002)|
|9.||File, Thomas M: 3 articles (07/2007 - 11/2002)|
|10.||Mandell, L: 3 articles (02/2006 - 06/2001)|
11/01/1999 - "In conclusion, gemifloxacin is a highly active fluoroquinolone that should prove clinically useful in the treatment of a wide range of infections. "
12/01/2009 - "Young women with uncomplicated urinary infections were evaluated in two random clinical studies; they were treated with 320 mg gemifloxacin once a day for three days. "
08/01/2003 - "This study confirms the enhanced potent activity of gemifloxacin against Gram-positive pathogens, its broad-spectrum, Gram-negative activity and indicates that gemifloxacin is likely to have an important role in treating patients with Gram-positive and/or Gram-negative infections."
02/01/2002 - "Based on our in vitro study results, we conclude that gemifloxacin may offer a therapeutic alternative for sinus infections."
12/01/2009 - "Gemifloxacin is a flouroquinolon with an excellent in vitro activity against many community acquired bacteria which cause respiratory or urinary infections. "
|2.||Respiratory Tract Infections (Respiratory Tract Infection)
07/01/2001 - "An open-label, non-comparative study assessed the clinical and bacteriological efficacy of gemifloxacin (320 mg, once-daily for 7 days) in lower respiratory tract infections (LRTI). "
07/01/2000 - "The efficacy of gemifloxacin, in comparison with other oral agents used to treat respiratory infections, has also been evaluated in a rat model using doses, and therefore AUC0-24h/MIC ratios, that approximate those in man. "
04/01/2008 - "Role of gemifloxacin in the management of community-acquired lower respiratory tract infections."
12/01/2006 - "Gemifloxacin demonstrated excellent clinical success in community-acquired lower respiratory infections, has an acceptable safety profile, and is a cost-effective alternative in the management of LRTIs including those caused by resistant pathogens."
05/01/2005 - "Due to its potent activity against many common gram-positive and gram-negative respiratory pathogens, its proven clinical efficacy, and its favorable safety profile, gemifloxacin is a highly effective empiric treatment for community-acquired lower respiratory tract infections."
07/01/2012 - "Hence, this study was planned to evaluate the efficacy of gemifloxacin as an empirical therapy in pneumonia. "
03/01/2013 - "The study group included patients with culture-confirmed pulmonary TB who initially received gemifloxacin for suspected community-acquired pneumonia (CAP). "
07/01/2012 - "Patients with clinical features of community acquired pneumonia (CAP) who fulfilled the inclusion criteria received treatment with oral gemifloxacin 320 mg once daily for 5-7 days. "
07/01/2012 - "Efficacy and safety of oral gemifloxacin for the empirical treatment of pneumonia."
08/01/2008 - "Role of gemifloxacin in community-acquired pneumonia."
01/01/2009 - "Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis."
05/01/2005 - "In clinical studies involving both hospitalized and outpatient populations, gemifloxacin has been highly effective in the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis. "
02/01/2012 - "The aim of the study was to evaluate the comparative effectiveness and safety of gemifloxacin for the treatment of patients with community-acquired pneumonia (CAP) or acute exacerbation of chronic bronchitis (AECB). "
02/01/2012 - "Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials."
07/01/2004 - "To evaluate the microbiology, pharmacokinetic parameters, drug interactions, and results of the available clinical trials of gemifloxacin for the treatment of community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB). "
|5.||Urinary Tract Infections (Urinary Tract Infection)
12/01/2001 - "Although clinical trials have shown that gemifloxacin is effective for the treatment of uncomplicated urinary tract infections, whether an oral dosage of 320 mg of gemifloxacin once daily is also adequate for the treatment of complicated urinary tract infections has yet to be confirmed."
02/01/2001 - "In conclusion, the results of these studies, combined with the antibacterial spectrum and potency, support the further investigation of once-daily administration of gemifloxacin for indications such as respiratory tract and urinary tract infections."
05/01/2000 - "Preliminary results from phase II trials show that oral gemifloxacin 320 mg/day produced bacteriological responses of 94.7% in patients with acute exacerbations of chronic bronchitis and 95% of patients with uncomplicated urinary tract infections. "
04/01/2000 - "These data demonstrate the potential benefit of gemifloxacin in the treatment of Gram-negative urinary tract infection and Gram-positive skin and soft tissue infection."
04/01/2001 - "Gemifloxacin is a fluoroquinolone antibacterial compound with enhanced affinity for bacterial topoisomerase IV and is being developed for the treatment of respiratory and urinary tract infections. "
|8.||Anti-Infective Agents (Microbicides)
|10.||sparfloxacin (AT 4140)